PMID- 37183203
OWN - NLM
STAT- MEDLINE
DCOM- 20230602
LR  - 20230623
IS  - 1573-7276 (Electronic)
IS  - 0262-0898 (Print)
IS  - 0262-0898 (Linking)
VI  - 40
IP  - 3
DP  - 2023 Jun
TI  - Histopathological growth patterns of neuroendocrine tumor liver metastases.
PG  - 227-234
LID - 10.1007/s10585-023-10211-z [doi]
AB  - Histopathological growth patterns (HGPs) of liver metastases represent a 
      potential biomarker for prognosis after resection. They have never been studied 
      in neuroendocrine tumor liver metastases (NETLM). This study evaluated if 
      distinct HGPs can be observed in resected NETLM and if they have prognostic 
      value. Sixty-three patients who underwent resection of NETLM between 01-01-2001 
      and 31-12-2021 were retrospectively included. HGPs were scored on 
      Haematoxylin&Eosin slides using light microscopy, distinguishing desmoplastic- 
      (dHGP), pushing- (pHGP) and replacement HGP (rHGP). Average HGP scores were 
      calculated per patient. Each patient was classified according to predominant HGP. 
      Overall and Disease-Free Survival (OS and DFS) were evaluated through 
      Kaplan-Meier analysis and Cox regression. Eighteen patients had predominant dHGP 
      (29%), 33 had predominant pHGP (52%) and 11 had predominant rHGP (17%). One 
      patient had mixed HGP (2%). Five-year OS was 76% (95%CI: 66-87%) for the overall 
      cohort. Five-year OS was 92% (95%CI: 77-100%) for dHGP, was 73% (95%CI: 59-91%) 
      for pHGP, 50% (95%CI: 25-100%) for rHGP. Five-year DFS was 39% (95%CI: 19-83%) 
      for dHGP, 44% (95%CI: 27-71%) for rHGP and 50% (95%CI: 23-100%) for pHGP. There 
      was no significant association between HGP and OS or DFS in multivariable 
      analysis. Distinct HGPs could be identified in NETLM. In patients who underwent 
      resection of NETLM, no association was found between HGPs and postoperative 
      survival. Half of the patients with NETLM have a predominant pushing growth 
      pattern, which is a rare growth pattern in liver metastases from breast and 
      colorectal cancer.
CI  - (c) 2023. The Author(s).
FAU - Meyer, Y
AU  - Meyer Y
AD  - Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus University 
      Hospital, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
FAU - Bohlok, A
AU  - Bohlok A
AD  - Institut Jules Bordet, Surgical Oncology, Universite Libre de Bruxelles, 
      Brussels, Belgium.
FAU - Olthof, P
AU  - Olthof P
AD  - Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus University 
      Hospital, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
FAU - Donckier, V
AU  - Donckier V
AD  - Institut Jules Bordet, Surgical Oncology, Universite Libre de Bruxelles, 
      Brussels, Belgium.
FAU - Doukas, M
AU  - Doukas M
AD  - Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
FAU - Lucidi, V
AU  - Lucidi V
AD  - Hopital Erasme, Department of Abdominal Surgery, Universite Libre de Bruxelles, 
      Brussels, Belgium.
FAU - Vermeulen, P
AU  - Vermeulen P
AD  - Translational Cancer Research Unit (GZA Hospitals and University of Antwerp), 
      Antwerp, Belgium.
FAU - Grunhagen, D
AU  - Grunhagen D
AD  - Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus University 
      Hospital, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
FAU - Verhoef, C
AU  - Verhoef C
AD  - Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus University 
      Hospital, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 
      c.verhoef@erasmusmc.nl.
LA  - eng
PT  - Journal Article
DEP - 20230514
PL  - Netherlands
TA  - Clin Exp Metastasis
JT  - Clinical & experimental metastasis
JID - 8409970
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - *Colorectal Neoplasms/pathology
MH  - *Neuroendocrine Tumors/surgery
MH  - *Liver Neoplasms/secondary
MH  - Prognosis
MH  - Hepatectomy
PMC - PMC10232551
OTO - NOTNLM
OT  - Histopathological growth patterns
OT  - Neuroendocrine tumour liver metastases
OT  - Prediction
OT  - Prognosis
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2023/05/15 00:42
MHDA- 2023/06/02 06:43
PMCR- 2023/05/14
CRDT- 2023/05/14 23:04
PHST- 2023/02/05 00:00 [received]
PHST- 2023/05/09 00:00 [accepted]
PHST- 2023/06/02 06:43 [medline]
PHST- 2023/05/15 00:42 [pubmed]
PHST- 2023/05/14 23:04 [entrez]
PHST- 2023/05/14 00:00 [pmc-release]
AID - 10.1007/s10585-023-10211-z [pii]
AID - 10211 [pii]
AID - 10.1007/s10585-023-10211-z [doi]
PST - ppublish
SO  - Clin Exp Metastasis. 2023 Jun;40(3):227-234. doi: 10.1007/s10585-023-10211-z. 
      Epub 2023 May 14.